CBT, SSRIs Effectively Cut Anxiety Symptoms in Childhood

Share this content:
CBT, SSRIs Effectively Cut Anxiety Symptoms in Childhood
CBT, SSRIs Effectively Cut Anxiety Symptoms in Childhood

TUESDAY, Sept. 5, 2017 (HealthDay News) -- Cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are effective for reducing symptoms of anxiety in childhood, according to a review published online Aug. 31 in JAMA Pediatrics.

Zhen Wang, Ph.D., from the Mayo Clinic Evidence-Based Practice Centre in Rochester, Minn., and colleagues examined the comparative effectiveness and adverse events of CBT and pharmacotherapy for childhood anxiety disorders. Data were included for 7,719 patients from 115 studies.

The researchers found that SSRIs significantly reduced primary anxiety symptoms and increased remission and response (relative risk, 2.04 and 1.96, respectively) compared with pill placebo. Clinician-reported primary anxiety symptoms were significantly reduced by serotonin-norepinephrine reuptake inhibitors (SNRIs). Neither benzodiazepines nor tricyclics significantly reduced anxiety symptoms. CBT significantly improved primary anxiety symptoms, remission, and response compared with wait-listing/no treatment. Primary anxiety symptoms were reduced more with CBT than fluoxetine, and remission was improved more with CBT than sertraline. Compared with either treatment alone, the combination of sertraline and CBT significantly reduced clinician-reported primary anxiety symptoms and response. Adverse events were common with medications but not CBT. Suicidality could not be assessed with SSRIs or SNRIs; a nonsignificant increase in suicidal ideation was seen with venlafaxine. There were fewer dropouts with CBT than pill placebo or medications.

"Head-to-head comparisons between various medications and comparisons with CBT represent a need for research in the field," the authors write.

One author reported receiving royalties from the sale of the mobile application: Mayo Clinic Anxiety Coach.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »